Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

INCY - Incyte Corp.


IEX Last Trade
65.66
-0.250   -0.381%

Share volume: 2,548,261
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$65.91
-0.25
-0.38%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
12%
Profitability 14%
Dept financing 7%
Liquidity 58%
Performance 0%
Company vs Stock growth
vs
Performance
5 Days
2.37%
1 Month
-3.14%
3 Months
14.59%
6 Months
9.47%
1 Year
0.63%
2 Year
-6.15%
Key data
Stock price
$65.66
P/E Ratio 
129.98
DAY RANGE
$64.98 - N/A
EPS 
$0.43
52 WEEK RANGE
$50.27 - $70.36
52 WEEK CHANGE
$0.01
MARKET CAP 
12.646 B
YIELD 
N/A
SHARES OUTSTANDING 
192.598 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
BETA 
0.31
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,761,686
AVERAGE 30 VOLUME 
$1,821,691
Company detail
CEO: Herve Hoppenot
Region: US
Website: https://www.incyte.com/
Employees: 2,600
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. our vision is to become a leader in the development and delivery of novel drugs for serious unmet medical needs. we have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds. the incyte corporate headquarters is located in wilmington, delaware, and more than 625 employees comprise our experienced management, discovery, clinical development and commercial teams. our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference by improving the lives of patients and building sustainable value for our shareholders. for more information about incyte, please visit our corporate website at www.incyte.com.

Recent news